NCT01568333View on ClinicalTrials.gov

A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

August 31, 2018

Conditions
Immune Thrombocytopenia
Interventions
DRUG

Decitabine

Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.

Trial Locations (1)

250012

Shandong University Qilu hospital, Jinan

All Listed Sponsors
collaborator

Qingdao University

OTHER

collaborator

Shandong Provincial Hospital

OTHER_GOV

lead

Shandong University

OTHER

NCT01568333 - A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia | Biotech Hunter | Biotech Hunter